BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu VaccineBiondvax Signs Lease Agreement • July 20th, 2017 • BiondVax Pharmaceuticals Ltd. • Biological products, (no disgnostic substances)
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today signed an agreement to lease approximately 1800m2 in the Jerusalem BioPark (JBP), located in the Ein Kerem Hadassah campus, next to Hadassah University Hospitals and Hebrew University’s Medical School. The mid-sized facility is planned to have capacity to annually produce tens of millions of doses of M-001 either in single-dose syringe or in bulk. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains.
